Core Insights - Resmed Inc. reported adjusted earnings per share (EPS) of $2.55 for Q4 fiscal 2025, reflecting a 22.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 3.66% [1] - The company's total revenue for Q4 was $1.35 billion, a 10.2% increase year-over-year, also exceeding the Zacks Consensus Estimate by 1.87% [3] - For the full fiscal year, adjusted EPS was $9.55, up 23.7% from fiscal 2024, and slightly above the Zacks Consensus Estimate by 0.5% [2] Revenue Performance - Q4 revenues from the Sleep and Breathing Health segment reached $1.18 billion, a 10.2% increase year-over-year, exceeding projections [5] - Device revenues within this segment were $693.9 million, up 9.3%, with notable growth in the U.S., Canada, and Latin America [5] - The Residential Care Software segment saw revenues grow 9.9% year-over-year to $167 million, aligning with expectations [7] Margin and Cost Analysis - Adjusted gross profit for Q4 was $827.9 million, a 14.4% increase, with an adjusted gross margin of 61.4%, up 227 basis points year-over-year [9] - Adjusted operating income rose 19% to $476.4 million, with an adjusted operating margin expanding 260 basis points to 35.3% [10] Financial Position - At the end of Q4, Resmed had cash and cash equivalents of $1.21 billion, significantly up from $238.4 million at the end of fiscal 2024 [11] - Total debt decreased to $668.3 million from $707.2 million at the end of fiscal 2024 [11] - The company generated cumulative net cash from operating activities of $1.75 billion, compared to $1.40 billion in the previous year [11] Shareholder Returns - In Q4, Resmed paid out $78 million in dividends and repurchased 419,000 shares for $100 million as part of its capital management strategy [12] Strategic Developments - The growth in sales was attributed to strong global demand for sleep and breathing health devices and the expansion of the digital health ecosystem [13] - The acquisition of VirtuOx enhanced Resmed's capabilities in providing at-home diagnostic services, supporting earlier patient care [14] - Improvements in gross margin were driven by efficiencies in procurement, manufacturing, and logistics, along with favorable currency movements [15]

Core Insights - Resmed Inc. reported a strong performance for the fourth quarter of fiscal year 2025, with a 10% increase in revenue and significant growth in earnings per share, driven by robust demand for sleep and breathing health devices and an expanding digital health ecosystem [2][3][5] Financial Results and Operating Metrics - Revenue for the quarter reached $1.348 billion, a 10% increase compared to the previous year, with a 9% increase on a constant currency basis [4][6] - Gross margin improved to 60.8%, up 230 basis points year-over-year, while non-GAAP gross margin increased to 61.4% [4][6] - Non-GAAP diluted earnings per share rose by 23% to $2.55, with net income increasing by 30% to $380 million [6][14] - Operating cash flow for the quarter was $539 million, reflecting strong operational performance [5][14] Year-over-Year Performance - For the full fiscal year 2025, total revenue was $5.146 billion, marking a 10% increase from the previous year [6][25] - The company achieved a net income of $1.401 billion for the year, a 37% increase compared to the prior year [6][25] - Non-GAAP diluted earnings per share for the full year increased by 24% to $9.55 [6][25] Business Segments and Regional Performance - Revenue growth was driven by a 9% increase in the U.S., Canada, and Latin America, and a 9% increase in Europe, Asia, and other markets on a constant currency basis [9][25] - The Residential Care Software segment also saw a 9% increase in revenue, indicating strong organic growth [9][25] Strategic Initiatives - The company announced the acquisition of VirtuOx, enhancing its capabilities in at-home diagnostic services for sleep and respiratory conditions [14] - Resmed continues to invest in innovation and digital health capabilities to improve patient care and expand access to healthcare solutions [4][14] Dividend and Shareholder Returns - The board declared a quarterly cash dividend of $0.60 per share, representing a 13% increase from the previous quarter [11][14] - During the quarter, Resmed repurchased 419,000 shares for $100 million as part of its capital management strategy [14]

Core Insights - ResMed Inc reported third-quarter adjusted EPS of $2.37, slightly above the consensus estimate of $2.36 [1] - Quarterly sales rose 8% year-over-year to $1.29 billion, matching estimates, with a 9% increase on a constant currency basis [1] - Gross margin improved by 140 basis points to 59.3%, driven by manufacturing efficiencies and favorable product mix [1] Financial Performance - Adjusted operating income increased by 13% to $444.6 million [2] - Adjusted net income rose by 11% to $348.5 million [2] - Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9% [3] - Revenue in Europe, Asia, and other markets, excluding Residential Care Software, increased by 8% on a constant currency basis [3] Product and Market Insights - Increased demand for sleep devices and growth in the Residential Care Software business contributed to sales growth [1] - Residential Care Software revenue grew by 10% on a constant currency basis, indicating continued organic growth [3] Regulatory and Analyst Commentary - Management confirmed that ResMed's products are exempt from tariffs under the Nairobi Protocol, which was approved in 2009 [2][4] - Analyst reactions include an 11% increase in ResMed stock price, with various price target adjustments from different firms [3][4]

Core Insights - Resmed Inc. reported strong financial performance for the third quarter of fiscal year 2025, with significant revenue growth, margin expansion, and double-digit earnings per share (EPS) growth driven by robust customer demand for its products and software solutions [2][3]. Financial Performance - Revenue for the quarter ended March 31, 2025, was $1,291.7 million, an increase of 8% year-over-year, and 9% on a constant currency basis [4][6]. - Gross margin improved by 140 basis points to 59.3%, while non-GAAP gross margin also increased by 140 basis points to 59.9% [4][6]. - Income from operations rose by 14% to $426.3 million, with non-GAAP income from operations increasing by 13% to $444.6 million [4][6]. - Net income for the quarter was $365 million, representing a 21% increase compared to the previous year, and diluted EPS was $2.48, up 22% [4][6]. Operational Highlights - The company emphasized its commitment to addressing the needs of over 2.3 billion people globally with sleep health and breathing health issues [3]. - Resmed's Residential Care Software revenue grew by 10% on a constant currency basis, reflecting continued organic growth in this segment [9]. - The company reported operating cash flow of $579 million for the quarter, with $107 million received in tax refunds from the IRS [5][9]. Product and Market Performance - Revenue in the U.S., Canada, and Latin America grew by 9%, while revenue in Europe, Asia, and other markets increased by 8% on a constant currency basis [9]. - The demand for sleep devices and masks, as well as growth in the Residential Care Software business, contributed to the overall revenue increase [9][24]. Dividend Declaration - The board of directors declared a quarterly cash dividend of $0.53 per share, with a record date of May 8, 2025, and payable on June 12, 2025 [10].